Campbell & Co Investment Adviser’s Regenxbio RGNX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-155,887	Closed	-$1.11M	–	1418
2025 Q1	$1.11M	Buy	+155,887	New	+$1.16M	0.09%	389
2024 Q2	–	Sell	-34,041	Closed	-$717K	–	1296
2024 Q1	$717K	Buy	34,041 +18,236	+115%	+$324K	0.06%	535
2023 Q4	$284K	Buy	+15,805	New	+$278K	0.03%	938
2022 Q4	–	Sell	-23,145	Closed	-$612K	–	960
2022 Q3	$612K	Buy	+23,145	New	+$687K	0.14%	251
2018 Q4	–	Sell	-2,800	Closed	-$211K	–	475
2018 Q3	$211K	Buy	+2,800	New	+$202K	0.14%	323

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Campbell & Co Investment Adviser's RGNX Position: Q2 2025 in Review

Campbell & Co Investment Adviser sold out of Regenxbio (RGNX) in Q2 2025, closing a stake of 155,887 shares — an estimated $1.11M sold.

Campbell & Co Investment Adviser first reported a position in RGNX in Q3 2018 and held it in 5 quarters. The position peaked at $1.11M in Q1 2025. 159 funds tracked by Wall St. Rank hold RGNX as of Q2 2025.

Campbell & Co Investment Adviser reported no remaining Regenxbio position as of Q2 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 155,887 Regenxbio shares in Q2 2025, an estimated $1.11M.
Campbell & Co Investment Adviser first reported a position in Regenxbio in Q3 2018 and held it in 5 quarters.
Campbell & Co Investment Adviser's Regenxbio position peaked at $1.11M in Q1 2025.
159 funds tracked by Wall St. Rank held Regenxbio as of Q2 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2025, filed 7 Aug 2025.